<DOC>
	<DOC>NCT00319033</DOC>
	<brief_summary>This study will asses the long term safety and efficacy of oral bosentan to patients suffering from Interstitial Lung Disease.</brief_summary>
	<brief_title>Open-label Study With Bosentan in Interstitial Lung Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Scleroderma, Systemic</mesh_term>
	<mesh_term>Scleroderma, Diffuse</mesh_term>
	<mesh_term>Lung Diseases, Interstitial</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>To have completed the 12month treatment period of the AC052330/BUILD 2. Women should not be pregnant Women of childbearing potential must have a negative pretreatment pregnancy test and use a reliable method of contraception Signed informed consent prior to initiation of any studymandated procedure Any major violation of the protocol AC052330.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>interstitial lung disease</keyword>
	<keyword>scleroderma</keyword>
	<keyword>bosentan</keyword>
</DOC>